Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation and invest...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kunadt, Désirée (VerfasserIn) , Krämer, Alwin (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Bornhäuser, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 05 September 2022
In: Journal of hematology & oncology
Year: 2022, Jahrgang: 15, Pages: 1-15
ISSN:1756-8722
DOI:10.1186/s13045-022-01339-8
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13045-022-01339-8
Volltext
Verfasserangaben:Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Krämer, Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim H. Brümmendorf, Edgar Jost, Björn Steffen, Gesine Bug, Hermann Einsele, Dennis Görlich, Cristina Sauerland, Kerstin Schäfer-Eckart, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Bernhard Wörmann, Michael Kramer, Katja Sockel, Katharina Egger-Heidrich, Tobias Herold, Gerhard Ehninger, Andreas Burchert, Uwe Platzbecker, Wolfgang E. Berdel, Carsten Müller-Tidow, Wolfgang Hiddemann, Hubert Serve, Matthias Stelljes, Claudia D. Baldus, Andreas Neubauer, Johannes Schetelig, Christian Thiede, Martin Bornhäuser, Jan M. Middeke, Friedrich Stölzel and the A.M.L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL)
Beschreibung
Zusammenfassung:The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation and investigated outcome in respect to IDH1/2 mutational subgroups (IDH1 R132C, R132H and IDH2 R140Q, R172K).
Beschreibung:Gesehen am 16.11.2022
Beschreibung:Online Resource
ISSN:1756-8722
DOI:10.1186/s13045-022-01339-8